Home / Irbesartan / Canada
CA ATC C09CA04 · updated 2 Nov 2026
Irbesartan shortage in Canada
Is there an Irbesartan shortage in Canada?
Yes. As of 2 Nov 2026, 13 Irbesartan products are reported short in Canada, the first since 17 Sep 2018. No return date has been given. Main reason: manufacturing problem.
Also short in Italy, Czechia, Sweden, Japan, Australia. All countries.
Affected products in Canada
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CA | BIO-IRBESARTAN (100) | BIOMED PHARMA | 17 Sep 2018 | not given | Increased demand Demand increase for the drug |
| CA | AURO-IRBESARTAN (100) | AURO PHARMA INC | 17 Oct 2018 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | AURO-IRBESARTAN (100) | AURO PHARMA INC | 17 Oct 2018 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | AURO-IRBESARTAN (100) | AURO PHARMA INC | 17 Oct 2018 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | APO-IRBESARTAN (100 BTL) | APOTEX INC | 5 Nov 2018 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | BIO-IRBESARTAN (100) | BIOMED PHARMA | 10 Mar 2019 | not given | Distribution or logistics Delay in shipping of the drug |
| CA | BIO-IRBESARTAN (100) | BIOMED PHARMA | 12 Mar 2019 | not given | Distribution or logistics Delay in shipping of the drug |
| CA | JAMP-IRBESARTAN (100) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-IRBESARTAN (100) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-IRBESARTAN (100) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-IRBESARTAN (28) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-IRBESARTAN (28) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-IRBESARTAN (28) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
Source
Health Canada, Health Product Shortages Canada. Official list. Mandatory company reports since 2017: actual and anticipated shortages, plus products about to be discontinued.